RCA-SHA: Citrate Versus Heparin Anticoagulation: Effect on Molecules Clearances

Sponsor

Hospices Civils de Lyon (Other)

Overall Status

Unknown status

CT.gov ID

NCT01839578

Collaborator

(none)

Enrollment

Location

Arms

Duration (Months)

1.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Sepsis is responsible for 50% of all acute kidney injury (AKI) in intensive care units (ICUs), contributing greatly to multiple organ dysfunction syndrome (MODS). Special types of continuous renal replacement therapies (CRRT) have been proposed as adjuvant therapies for septic shock due to their ability to remove middle molecular weight molecules such as inflammatory mediators involved in MODS pathophysiology. These therapies are called extracorporeal " blood purification " therapies.

When CRRT is used, an anticoagulation is required to prevent clotting of the extracorporeal circuit, possibly causing bleeding in selected patients. Many anticoagulation strategies have been proposed and the most commonly used in 2013 is still unfractionated heparin. Regional citrate anticoagulation (RCA) is an interesting alternative as it dramatically decreases the bleeding risk.

The investigators hypothesize that the use of citrate with Super High Flux Continuous Veno-Venus Hemodialysis (SHF-CVVHD) would be highly beneficial over time by preserving the filter effectiveness via limiting protein adhesion (which subsequently reduces filter pore sizes (protein cake)), as compared to heparin. Consequently, higher clearances of the inflammatory mediators could be maintained over time with citrate as compared to heparin anticoagulation. In other words, for the same duration of filter use, middle molecular weight molecules and cytokines clearances would be greater with citrate as compared to heparin. To test this hypothesis, the investigators will perform a clinical randomized controlled trial which aim would be to compare middle molecular weight molecules and cytokines clearances in SHF-CVVHD using RCA versus systemic heparin anticoagulation in septic patients with AKI.

Condition or Disease	Intervention/Treatment	Phase
Septic Shock	Drug: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation) Drug: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)	N/A

Study Design

Study Type:

Interventional

Anticipated Enrollment :

30 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Regional Citrate Versus Systemic Heparin Anticoagulation for Super High-flux Continuous Hemodialysis in Septic Shock: Effect on Middle Molecular Weight Molecules Clearances

Study Start Date :

May 1, 2013

Anticipated Primary Completion Date :

Nov 1, 2014

Anticipated Study Completion Date :

Apr 1, 2015

Arms and Interventions

Arm	Intervention/Treatment
Experimental: RCA Group SHF-CVVHD with regional citrate anticoagulation	Drug: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation) Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared. Ci-Ca protocole for MultiFiltrate® CRRT machine : 4% trisodium citrate solution Calcium chloride solution (100 mmol/L) Dialysate flow rate: 35 ml/kg/h Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3 Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L. Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L. Blood flow adapted to the acid-base status
Experimental: Heparin group SHF-CVVHD with systemic heparin anticoagulation	Drug: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin) Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared. Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value. Standard dialysate for CRRT : Prismasol® K2 solution Dialysate flow rate: 35 ml/kg/h Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of

Arm

Intervention/Treatment

Experimental: RCA Group

SHF-CVVHD with regional citrate anticoagulation

Drug: Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)

Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared. Ci-Ca protocole for MultiFiltrate® CRRT machine : 4% trisodium citrate solution Calcium chloride solution (100 mmol/L) Dialysate flow rate: 35 ml/kg/h Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3 Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L. Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L. Blood flow adapted to the acid-base status

Experimental: Heparin group

SHF-CVVHD with systemic heparin anticoagulation

Drug: Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)

Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared. Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value. Standard dialysate for CRRT : Prismasol® K2 solution Dialysate flow rate: 35 ml/kg/h Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of

Outcome Measures

Primary Outcome Measures

Middle molecular weight molecules clearances [18 months]
At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), blood and post-filter samplings will be taken in order to calculate kappa and lambda light chains of immunoglobulin clearances.

Secondary Outcome Measures

Clearances of cytokines and molecules of interest [T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h]
At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), sampling will be simultaneously collected from blood and post-filter in order to determine cytokines (IL-1 ra, IL-10, IL-6, IL-8, β2microglobuline), urea, creatinine and albumin clearances.
Hemodynamic parameters [T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h]
At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), clinical data and blood sampling will be collected in order to assess mean arterial pressure, heart rate, vasopressor requirement and lactate level.
Respiratory parameters [(T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h),]
At each time point of the study (T=1h,T=4h,T=12h,T=24h, T=48h, and T=72h), PaO2/FIO2 ratio will be measured by blood sampling and clinical data collection.
mortality [28th day]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female critically ill patients over the age of 18 years old
Acute Kidney Injury requiring CRRT defined using the Risk, Injury, Failure, Loss, End-stage renal disease (RIFLE) classification with criterion I or worse.
Septic shock as defined by the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.
Written informed consent obtained from the patient or a patient's legal representative
Patient patient's legal representative able to agree to patient's enrollment in the study with informed consent.

Exclusion Criteria:

Pregnancy
Participation in another research study protocol
Known heparin induced thrombopenia or contraindication to heparin
Pre-existing chronic renal failure on chronic dialysis
Therapeutic anticoagulation with heparin for another reason (e.g. chonic arrhythmia)
Severe liver failure (15% prothrombin time)